title: The use of recombinant activated factor VII in the circumcision operation in the case of a congenital factor VII deficiency.
abstract: Congenital factor VII deficiency is a rare autosomal recessive hemorrhagic disorder and surgery is normally the cause of excessive bleeding. In this report, we describe the first case with congenital factor VII deficiency admitted to our clinics for the sunnet operation (circumcision), in which recombinant activated factor VII (rFVIIa; NovoSeven) was used to manage the bleeding. The patient was an 8-year old boy with moderate factor VII deficiency (factor VII level, 4%), and rFVIIa was administered at a dose of 20 microg/kg per dose during the circumcision operation. The same dose was repeated at 2, 4, 6, 9, 12, 15, 18, 21 and 24 h post operation. The circumcision operation could therefore be safely performed in patients with congenital factor VII using rFVIIa.
authors.affiliation: Department of Pediatrics, Suleyman Demirel University, Isparta 32040, Turkey. dcanatan@superonline.com
authors.forename: Duran
authors.initials: D
authors.lastname: Canatan
authors.forename: Erdal
authors.initials: E
authors.lastname: Eren
authors.forename: I Faruk
authors.initials: IF
authors.lastname: Ozgüner
authors.forename: Handan
authors.initials: H
authors.lastname: Duman
authors.forename: Cağatay
authors.initials: C
authors.lastname: Eren
authors.forename: Ilker
authors.initials: I
authors.lastname: Büyükyavuz
authors.forename: Cağri
authors.initials: C
authors.lastname: Savaş
mesh_terms: D016063:Blood Loss, Surgical / Q000517:prevention & control*; D002648:Child; D002944:Circumcision, Male / Q000009:adverse effects*; D000075202:Contraindications; D005168:Factor VII Deficiency / Q000188:drug therapy*; D015942:Factor VIIa / Q000627:therapeutic use*; D006801:Humans; D019934:International Normalized Ratio; D008297:Male; D011994:Recombinant Proteins / Q000627:therapeutic use*
chemical_list: D011994:Recombinant Proteins; D015942:Factor VIIa